Pharmaceutical Industry Exploits Loopholes in FDA Regulation, Trump-Connected Lobbying Firms Reap Benefits
Original framing: “STAT+: Lobbying firms with close ties to Trump draw pharma industry clients” — STAT News
The history of regulatory capture in the US is marked by numerous examples of corporate interests influencing policy, from the tobacco industry's influence on nicotine regulation to the pharma industry's influence on opioid prescribing guidelines. This pattern of influence highlights the need for stronger regulatory oversight and more transparent lobbying practices.
The pharma industry's influence on FDA regulation reveals a deeper issue of regulatory capture, where corporate interests override public health concerns.
This phenomenon is not new, as similar patterns have emerged in the past, such as the tobacco industry's influence on nicotine regulation. The current situation highlights the need for stronger regulatory oversight and more transparent lobbying practices. By prioritizing public health over corporate interests, promoting transparency in lobbying practices, and engaging marginalized communities in healthcare policy, we can work towards a more equitable and just healthcare system that prioritizes the well-being of individuals and communities over profit-driven medicine.